Introduction
Pancreatic ductal adenocarcinoma is a highly aggressive and almost universally fatal cancer with an average five-year survival rate of 5% across all stages (1) . The poor prognosis of pancreatic cancer patients is due to inadequate early detection and ineffective treatments once diagnosed. Due to its asymptomatic nature in the early stages, over 85% of patients are diagnosed at stages III-IV with metastases, eliminating surgery as a curative option (1) (2) . Furthermore, ultrasound-guided needle biopsy, commonly used to diagnose pancreatic adenocarcinoma, requires suspected tumors to be at least 1 cm 3 (3) . The current gold-standard treatment for pancreatic cancer, gemcitabine, only enhances survival by 6.7 months. Advancements in chemotherapy such as FOLFIRONIX and nab-Paclitaxel minimally increase median survival, with survival rates of 11 and 8.5 months, respectively (4) .
The underlying biology of pancreatic ductal adenocarcinoma can make these tumors particularly resistant to chemotherapy. The dense desmoplastic stroma and poor vascularity of these tumors inhibits the accumulation of traditional chemotherapies and prevents sufficient drug concentrations from being attained within the tumor (7) . Nanoparticle drug carriers can be an effective strategy for overcoming these extracellular barriers to drug delivery by increasing the therapeutic load at tumor sites while decreasing systemic toxicity (8) (9) (10) . Enhanced accumulation at pathological sites can result in an increase in the drug's therapeutic efficacy and reduction of incidence and intensity of side effects, resulting in improved patient acceptance, compliance and prognosis (8, (12) (13) (14) .
Liposomes in particular have multiple desirable characteristics, such as the capacity for encapsulating large amounts of materials, the ability to protect these materials from degradation, and the capability for intracellular delivery through fusion with the plasma membrane (9) .
Liposomes are also permeable in environments with high collagen content, a trait of the extracellular matrices of solid pancreatic tumors (10) (11) . In addition to being drug carriers, liposomes can also encapsulate contrast agents for diagnostic imaging, thus combining diagnostic and therapeutic functions into one system. These particles, termed "theranostic nanoparticles", are a novel approach for detecting, monitoring, and treating cancer (12) (13) (14) (15) . The contrast agents loaded into theranostic nanoparticles allow tracking of nanoparticle accumulation and biodistribution using standard techniques such as planar fluorescent imaging (16) . An important characteristic of theranostic nanoparticles is that a targeting ligand can be covalently attached to the outside of the particle so that it will preferentially accumulate at the tumor site (15) (16) (17) (18) .
Syndecan-1 (Sdc1) can be used to specifically target pancreatic adenocarcinoma due to its known interactions with Insulin-like Growth Factor 1 receptor (IGF1R) (19) (20) (21) . IGF1R has been shown to be highly expressed in pancreatic adenocarcinoma and other metastatic cancers with an important role in cell proliferation, tumor metastasis, and anti-apoptotic pathways (22) (23) (24) (25) (26) . High IGF1R expression correlates to resistance to chemotherapy and radiation-induced apoptosis and is a marker for poor prognosis in pancreatic, breast, lung, and prostate cancers (23) (24) (25) (26) . The ectodomain of Sdc1 binds to IGF1R to activate αvβ3 integrin in many aggressive cancers, a mechanism not found in non-malignant epithelial cells (20) (21) . Furthermore, Sdc1-tagged optical probes have already been shown to bind specifically to pancreatic tumor cells in vivo (27) . Thus, covalently attaching Sdc1 to the outside of a liposome may produce a theranostic nanoparticle that is specific to pancreatic adenocarcinoma, potentially leading to an improved method of transporting imaging agents and chemotherapies directly to the tumor site.
Because Sdc1-tagged liposomes can encapsulate a variety of optically active molecules, or chromophores, they can be imaged using traditional imaging techniques (16) . However, multi-6 spectral optoacoustic tomography (MSOT) offers several advantages over traditional nuclear imaging modalities. MSOT operates via the photoacoustic effect, wherein a medium excited by pulsed laser light subsequently emits an acoustic wave. Chromophores absorb a photon and enter an excited state, generating heat upon relaxation. This pulse of heat leads to an increase in temperature and local pressure, termed thermoelastic expansion. Propagation of the pressure differential results in the formation of an acoustic wave, which can then be recorded with ultrasound detectors to create high-resolution 3D images (28) (29) . Expansion of endogenous and exogenous chromophores occur at specific excitation wavelengths, allowing for selective imaging of compounds of interest. Due to the low-scattering characteristic of ultrasonic waves, images do not suffer from the light scattering or signal attenuation that limits optical and fluorescent imaging.
Additional advantages include an enhanced spatial resolution of up to 150 µm and accurate 3D imaging of deep tissue layers (29) (30) (31) (32) (33) . Furthermore, multi-wavelength measurements can be used to quantify spatially varying concentrations of chromophores within biological tissues (28) . MSOT can therefore be a valuable tool in determining the precise location and concentration of theranostic nanoparticles in vivo.
In this study, Syndecan-1 tagged liposomes were synthesized to encapsulate a near-infrared (NIR) fluorescent dye, CF-750 or propidium iodide (PI), to allow for tracking of the liposome in vivo or determine the potential of the liposome to release its cargo within a tumor cell, respectively ( Fig. 1 ). As a further control within experiments of the Syndecan-1 tagged liposome, untargeted liposomes were utilized. Untagged liposomes had no targeting ligand.
The specificity of Sdc1 liposomes for pancreatic adenocarcinoma was evaluated both in vitro and in vivo. Immunocytochemistry was performed to visualize IGF1R-dependent binding and endocytosis of Sdc1 and untagged liposomes. Sdc1 liposomes were systemically injected by 7 intravenous injection into an orthotopic mouse model to allow for in vivo tracking of biodistribution and accumulation. This study examines the feasibility of using Sdc1-tagged liposomes as a theranostic nanoparticle for pancreatic adenocarcinoma. 8 
Materials & Methods

Cell Culture
Pancreatic adenocarcinoma cell lines S2VP10 and S2013, metastatic subclones of the SUIT-2 line, were obtained from Dr. Michael A. Hollingsworth at the University of Nebraska.
Squamous cell carcinoma cell line SCC-1 was obtained from the University of Michigan.
Pancreatic adenocarcinoma cell line MiaPaCa-2 was obtained from ATCC (Manassas, VA). S2VP10, S2013, and SCC-1 cells were cultured in RPMI 1640 and MiaPaCa-2 cells in DMEM medium (Gibco, Grand Island, NY), supplemented with 10% Fetal Bovine Serum (Atlanta Biologicals, Flowery Branch, GA) and 1% L-Glutamine (Gibco). The cells were cultured at 37°C and 5% CO2. S2VP10 cells were infected with a retrovirus containing the firefly luciferase (Luc) gene (Stratagene, La Jolla, CA) and a luciferase-positive single cell clone, S2VP10L, was isolated (34) . Finally, Syndecan-1 (Sdc1) was purchased from Prospec (Rehovot, Israel).
Synthesis of Liposomes
Materials
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Synthesis of propidium iodide and CF-750 encapsulated liposomes
Naked liposomes were synthesized by thin film hydration method (35) . Soybean PC (0.0067 g), CAP (0.0023 g) and DOPE (0.0020 g) were dissolved in chloroform. Then, the chloroform was evaporated by heating at 70°C for 10 min in a rotary evaporator to get a thin film of lipids. The thin film was hydrated by adding 1 ml PBS (pH 7.4, 0.9% NaCl) and propidium iodide or CF-750 (1 mM, 0.1 ml) for 2 h at 70°C. Then, the liposomes were sonicated for 2 h at 70°C. Finally, liposomes were extruded four times through a polycarbonate filter (200 nm) at 70°C.
Conjugation of Syndecan-1 to dye-encapsulated liposomes
Syndecan-1 was conjugated to the dye-encapsulated naked liposomes by carbodiimide chemistry. Syndecan-1 (0.74 mM, 20 µl) was mixed with NHS (1 mM, 0.1 ml) and EDC (1 mM, 0.1 ml) and incubated for 6 h at room temperature at pH 7.5. Then, 1 ml of liposomes was added to this solution and mixed for 1 day at room temperature. The excess NHS and EDC were removed by dialysis, minimum 2000-3000 Da. The stock solution of Sdc1 conjugated liposomes was diluted further to get the desired concentration.
Characterization of Liposomes
DLS measurements
The size distribution of the liposomes was analyzed by dynamic light scattering (DLS) using a Zetasizer Nano-ZS (Malvern Instruments Ltd., Malvern, United Kingdom). The detection angle was 173° and the incident beam was a He-Ne ion laser (λ = 633 nm). Correlation functions were analyzed by a histogram method and used to determine the diffusion coefficient (D) of the liposomes in the sample. Hydrodynamic radius (Rh) was calculated from D by using Stokes-Einstein's equation: 10 where kB is Boltzmann's constant, T is absolute temperature, and η is solvent viscosity (36) .
Zeta-potential measurements
Electrophoretic mobility (μE) of the liposomes was measured at 25 °C with the Zetasizer Nano-ZS. The zeta-potential of the samples was calculated from μE using following
Smoluchowski's equation:
where ζ is the zeta-potential, ε the permittivity of solvent, and η the solvent viscosity (36) .
Transmission electron microscopy
10 µL of 1 mM liposomes were dropped on 200 mesh copper grids (Electron Microscopy Sciences, Hatfield, PA) and dried at room temperature for 5 h. Images were collected using the Phillips CM-10 transmission electron microscope at 80kV, equipped with a 15 megabyte SIA digital camera.
UV-Vis spectroscopy
The absorption spectrum for the CF-750 encapsulated liposomes was analyzed via UV- 
Orthotopic Pancreatic Cancer Xenografts
In Vivo Imaging and Reconstruction
Multispectral optoacoustic tomographic (MSOT) imaging was performed as described by 
Results
Western Blot
Western blot analysis was performed to evaluate the expression of IGF1R on the three different pancreatic adenocarcinoma cell lines (S2VP10L, MiaPaCa-2, and S2013). The head and neck squamous cell carcinoma cell line SCC-1 served as a negative control (22) . As expected, SCC-1 cells expressed much lower levels of IGF1R than pancreatic cancer lines ( Fig. 2A) . Less aggressive MiaPaCa-2 cells also had relatively low IGF1R expression. Highly aggressive and metastatic S2VP10L and S2013 cells had five-and seven-fold increase of IGF1R expression respectively compared to SCC-1 cells (Fig. 2B) . S2VP10L cells were chosen as the pancreatic cell line to be used for the remainder of the experiments due to their predictable behavior in vivo and relatively high levels of IGF1R expression.
Characterization of Liposomes
Liposomes were synthesized to encapsulate CF-750 dye or propidium iodide and tagged with Syndecan-1. Transmission electron microscopy (TEM) of the liposomes shows the average size to be 117 nm (Fig. 3C ). The size of liposomes observed by TEM is smaller than DLS (129 nm, Fig. 3A) , as TEM yields a number-averaged size whereas DLS does a Z-averaged size that takes into account hydration layers. Based on the low polydispersion index, the liposomes are uniform in size (Fig. 3A) . The liposomes also have a slight positive charge of 0.3 mV (Fig. 3B) .
UV-Vis Spectroscopy
The absorption spectrum for CF-750 encapsulated Sdc1 liposomes was analyzed using UV-Vis spectroscopy. The peak absorption of the liposomes was 750 nm, the same as the original dye ( Fig. 4) . Thus, encapsulating the dye within liposomes does not change the optical behavior of the dye.
Immunocytochemistry
Immunocytochemistry slides of S2VP10L and SCC-1 cells were treated with non-targeted and Sdc1 liposomes containing propidium iodide and imaged using Texas Red, DAPI, and FITC filters. Fluorescence seen using the Texas Red filter indicates propidium iodide (PI) uptake by the cell. In IGF1R-positive S2VP10L cells, there was greatly increased uptake of PI when treated with Sdc1-tagged liposomes (Fig. 5C ) compared to naked liposomes (Fig. 5B) . 5A ) and no green autofluorescence (Fig. 5D ).
Propidium iodide, when bound to nucleic acids, displays maximum excitation and emission values at 538 nm and 617 nm respectively and fluoresces red using the Texas Red filter. However, PI in its free form exhibits different optical characteristics: maximum excitation at 488 nm and emission at 590 nm (37) , fluorescing green using the FITC filter. This allows for distinction between excess dye bound on the cell surface versus internalized dye bound to nuclear or cytoplasmic nucleic acids.
In Vivo Imaging and Reconstruction
Syndecan-1-tagged liposomes were injected ten days post-implantation of the tumor.
Liposome accumulation in vivo was determined using MSOT imaging every 8 h for 24 h. 17 Representative location of organs as seen on the MSOT can be viewed in Figure 6 . Liposome accumulation in the tumor peaked at 8 h post-injection and declined within 24 h (Fig. 7C) . The highest region of photoacoustic signal was between 45 and 46 mm in the mouse, and corresponded with the location of the pancreatic tumors (Fig. 7A ). Low signal intensity was observed in the spleen and liver (Fig. 7B) , indicating significantly more liposomes accumulated in the tumor versus in the liver and kidney (p<0.05). Furthermore, orthogonal views of the tumor demonstrate probe accumulation along 3 spatial dimensions, and suggest liposome penetration and accumulation within the interior of the pancreatic tumor ( Fig. 7B) .
Ex Vivo Imaging of Organs
Ex vivo fluorescent imaging confirms accumulation of Sdc1-liposomes within organs (Fig.   8 ). Mice were euthanized 24 h post-liposomal injection. The pancreas, liver, and spleen were imaged using NIR fluorescent imaging with excitation 675 nm and emission 760 nm. Sdc1-tagged liposomes bound preferentially to the pancreas tumor with little off-target binding in the liver and spleen. Non-targeted liposomes accumulated primarily within the liver.
Discussion
This study investigated the feasibility of using Sdc1-tagged liposomes as a theranostic nanoparticle for detection and possible treatment of pancreatic adenocarcinoma. By utilizing fluorescent dyes, liposome specificity and unloading capability was assessed in vitro using immunocytochemistry. Accumulation time and specificity in vivo were analyzed by injecting the liposomes into an orthotopic mouse model and imaging using MSOT and ex vivo fluorescence imaging.
Treatment with liposome-encapsulated therapeutics has been shown to increase bioavailability of therapeutic agents at the tumor site, reduce off-target toxicity, and increase circulation time (39) (40) (41) . Many of these liposomes utilize the Enhanced Permeability and Retention effect (EPR), a phenomenon wherein particles around 100 nm accumulate in tumors due to leaky vasculature, to passively target cancerous tissues (38) . Sdc1-tagged liposomes were 117 nm in diameter, theoretically allowing them to diffuse into tumor sites via EPR. However, targeting IGF1R with the Sdc1 ligand utilizes a second mechanism to enhance specificity, active targeting.
Previous studies have shown that attaching a targeting ligand increases tumor targeting and intracellular uptake in tumor sites when compared to non-targeted liposomes (42) . In this project, Sdc1-tagged liposome and control (untagged) liposome specificities were compared using ex vivo analysis. Though some control liposomes may have reached the pancreatic tumor due to passive targeting from EPR and the leakiness of the blood vessels around the tumor, Sdc1-tagged liposomes showed greater accumulation within the pancreatic tumor and less off-target binding.
These results, congruent with previous findings, suggest that the active targeting of the Sdc1 ligand contributes most to the specificity of the Sdc1-tagged liposomes.
Cancer cells treated with targeted liposomes containing chemotherapeutic agents show enhanced cell death when compared to non-targeted liposomes due to enhanced receptor-mediated endocytosis (43) . This project showed that Sdc1-tagged liposomes are capable of fusing with cell membranes and unloading their contents into the cell, indicated by the presence of DNA-bound propidium iodide in S2VP10L cells treated with the liposomes. This result was observed in IGF1Rpositive S2VP10L cells and not in IGF1R-negative SCC1 cells, suggesting that the Sdc1-IGF1R
interaction facilitates endocytosis.
The specific unloading of liposomal contents to IGF1R-positive cells in vitro and low offtarget binding in vivo demonstrate the feasibility of using Syndecan-1 as a targeting ligand for a pancreatic theranostic nanoparticle. Because Sdc1-tagged liposomes specifically target and preferentially release contents to pancreatic adenocarcinoma, encapsulating a drug in these particles can reduce systemic toxicity, leading to decreased side effects and improved patient prognosis (8, (12) (13) (14) . Furthermore, the presence of a contrast agent allows for tracking of liposomal movement and accumulation and can be used to image pancreatic cancer in earlier stages using existing ultrasonic methods.
In this study, photoacoustic imaging was used to produce high resolution molecular images in vivo based on the absorption of contrast agents. It has previously been used to image both endogenous (such as melanin in the monitoring of melanoma) and exogenous (NIR dyes) chromophores in the context of cancer (44) . Though photoacoustic imaging is not currently widely 
